BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7768497)

  • 1. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
    Manesis EK; Giannoulis G; Zoumboulis P; Vafiadou I; Hadziyannis SJ
    Hepatology; 1995 Jun; 21(6):1535-42. PubMed ID: 7768497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
    Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
    Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
    Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
    Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
    Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire
    Hepatology; 2004 Dec; 40(6):1361-9. PubMed ID: 15565568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.
    Elba S; Giannuzzi V; Misciagna G; Manghisi OG
    Ital J Gastroenterol; 1994 Mar; 26(2):66-8. PubMed ID: 8032079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
    Barbare JC; Bouché O; Bonnetain F; Raoul JL; Rougier P; Abergel A; Boige V; Denis B; Blanchi A; Pariente A; Milan C; Bedenne L
    J Clin Oncol; 2005 Jul; 23(19):4338-46. PubMed ID: 15994145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
    Raoul JL; Guyader D; Bretagne JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
    J Nucl Med; 1994 Nov; 35(11):1782-7. PubMed ID: 7525901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
    Emons G; Ortmann O; Teichert HM; Fassl H; Löhrs U; Kullander S; Kauppila A; Ayalon D; Schally A; Oberheuser F
    Cancer; 1996 Oct; 78(7):1452-60. PubMed ID: 8839551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor?
    Farinati F; De Maria N; Marafin C; Fagiuoli S; Della Libera G; Naccarato R
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):145-50. PubMed ID: 7712307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of flutamide in the treatment of hepatocellular carcinoma.
    Chao Y; Chan WK; Huang YS; Teng HC; Wang SS; Lui WY; Whang-Peng J; Lee SD
    Cancer; 1996 Feb; 77(4):635-9. PubMed ID: 8616754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate.
    Stockland AH; Walser EM; Paz-Fumagalli R; McKinney JM; May GR
    Cardiovasc Intervent Radiol; 2007; 30(5):888-93. PubMed ID: 17619218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.
    Zavaglia C; De Carlis L; Alberti AB; Minola E; Belli LS; Slim AO; Airoldi A; Giacomoni A; Rondinara G; Tinelli C; Forti D; Pinzello G
    Am J Gastroenterol; 2005 Dec; 100(12):2708-16. PubMed ID: 16393224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
    Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
    Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma.
    Gallo C; De Maio E; Di Maio M; Signoriello G; Daniele B; Pignata S; Annunziata A; Perrone F;
    BMC Cancer; 2006 Jul; 6():196. PubMed ID: 16863588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the clinical characteristics among hepatocellular carcinoma of hepatitis B, hepatitis C and non-B non-C patients.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2022-7. PubMed ID: 14696457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
    Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
    Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose vitamin K3 infusion in advanced hepatocellular carcinoma.
    Sarin SK; Kumar M; Garg S; Hissar S; Pandey C; Sharma BC
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1478-82. PubMed ID: 16911696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo.
    Benson RC; Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Dorr FA
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):9-12. PubMed ID: 1948121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.